MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study
This post-market study is intended to assess the performance of the HTLV Blot 2.4 in repository serum/plasma specimens with neurological disorders (n=100) or an HTLV known positive infection (n=50).
HTLV-I Infections|HTLV-II Infections|Human T-lymphotropic Virus 1|Human T-lymphotropic Virus 2|HTLV I Associated T Cell Leukemia Lymphoma|HTLV I Associated Myelopathies
DIAGNOSTIC_TEST: MP Diagnostics HTLV Blot 2.4
To demonstrate ≥95% agreement of HTLV Blot 2.4 results with the Reference Core Laboratory HTLV Algorithm in 100 Neurological Disorder Specimens, 3 months|To demonstrate HTLV Blot 2.4 sensitivity of ≥97.5% in 50 HTLV Known Positive Specimens, 3 months
The HTLV Blot 2.4 Post-Market Clinical Study is an open-label, multi-center, single-blind clinical study of neurological disorders (n=100) and HTLV known-positive (KP) specimens (n=50). This study is being conducted to support additional labeling claims and to further assess the sensitivity and specificity of the HTLV Blot 2.4 in specimens with neurological disorders and HTLV known positive specimens.